Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesomet in hypothalamic injury-induced obesity
NCT03845075Phase 2Completed
- Sponsor
- Saniona
- Start
- Feb 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tesofensine in hypothalamic obesity (HO), sponsored by Saniona. Started Feb 2019; status: completed.
02
Drugs
tesofensine
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT03845075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845075.